Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2014
11/13/2014US20140335209 Pawpaw and/or peach derived composition
11/13/2014US20140335150 Therapeutic patch
11/11/2014US8883856 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors
11/11/2014US8883849 Treatment of sleep disturbances
11/11/2014US8883847 Compositions and methods of treatment using modulators of motoneuron diseases
11/11/2014US8883826 Alkynyl derivatives as modulators of metabotropic glutamate receptors
11/11/2014US8883715 Biocompatible polymers, process for their preparation and compositions containing them
11/11/2014US8883504 Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line
11/11/2014US8883198 Transdermal rivastigmine therapeutic system
11/11/2014US8882075 Furnace mount
11/04/2014US8877891 Method of producing a novel opioid peptide
11/04/2014US8877755 Dopamine-agonist combination therapy for improving sleep quality
11/04/2014US8877753 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
11/04/2014US8877750 2-oxy-benzoxazinone derivatives for the treatment of obesity
11/04/2014US8877726 Method and medicament for inhibiting the expression of a given gene
11/04/2014US8877247 Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
11/04/2014US8877236 Liposomes active in-vivo on neurodegenerative diseases
10/2014
10/30/2014US20140325691 Regulation of endogenous gene expression in cells using zinc finger proteins
10/30/2014US20140322232 Methods of administering anti-tnfalpha antibodies
10/28/2014US8871763 Use and application of a pharmaceutical composition containing a mixture of natural-origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies
10/28/2014US8871226 Methods and compositions for the treatment and diagnosis of cancer
10/23/2014US20140316151 Pasteurisation process for microbial cells and microbial oil
10/21/2014US8865767 Nutritional supplement composition promoting, increase, development, elevation and activation of “serotonin”
10/21/2014US8865709 Aminooxazole inhibitors of cyclin dependent kinases
10/21/2014US8865701 Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer'S disease
10/21/2014US8865219 Orodispersible tablets of bitter active principles
10/16/2014US20140309236 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
10/16/2014US20140308288 Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
10/14/2014US8859855 Chimeric PUFA polyketide synthase systems and uses thereof
10/14/2014US8859628 Method for preventing, treating and diagnosing disorders of protein aggregation
10/14/2014US8859621 Pharmaceutical formulations of modafinil
10/14/2014US8859619 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
10/14/2014US8859568 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy
10/14/2014US8859545 Tetrahydronaphthyridine and tetrahydropyrido[4,3-D]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases
10/14/2014US8859540 Use of dihydroimidazolones for the treatment of dogs
10/14/2014US8859538 Uses of substituted imidazoheterocycles
10/14/2014US8859537 Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
10/14/2014US8858928 Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
10/09/2014WO2014165827A1 Ppar agonists
10/09/2014WO2014165701A1 Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
10/09/2014WO2014165070A1 Substituted 2-azabicycles and their use as orexin receptor modulators
10/09/2014WO2014165065A1 Substituted piperidine compounds and their use as orexin receptor modulators
10/09/2014WO2014165043A1 Fragments, mutants and chimeric fusion proteins of leptin for treating alzheimer's disease
10/09/2014WO2014164756A1 Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
10/09/2014WO2014163643A1 Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
10/09/2014WO2014163518A1 Treatments involving eslicarbazepine or eslicarbazepine acetate
10/09/2014WO2014163416A1 Composition for life extension containing (+)-syringaresinol
10/09/2014WO2014163402A1 Composition for improving health and quality of life of women containing ginseng berry extract
10/09/2014WO2014163210A1 [11 c] and [18f] labeled 1,3-diphenyl-5-(pyrimidin-2-yl)-pyridin-2(1 h)-one derivatives and their use for pet imaging of the ampa receptor
10/09/2014WO2014163162A1 Heterocyclic compound
10/09/2014WO2014163161A1 Heterocyclic compound
10/09/2014WO2014163152A1 Non-rem sleep-promoting agent, deep sleep-promoting agent and natural sleep-inducing agent
10/09/2014WO2014163151A1 Yeast culture, and composition for internal application
10/09/2014WO2014163150A1 Composition for internal use
10/09/2014WO2014163147A1 Salt of pyrazoloquinoline derivative, and crystal thereof
10/09/2014WO2014163146A1 Pyridinylpyrazoloquinoline compound
10/09/2014WO2014163132A1 Solid composition of amino carboxylate salt
10/09/2014WO2014162737A1 Tau aggregation inhibitor
10/09/2014WO2014162276A1 A composition for treating neuropathy, a process and a method of treatment thereof
10/09/2014WO2014162195A1 Two-component formulations, methods and procedures to prevent or reduce trauma-induced neuropathology and neurodegeneration
10/09/2014WO2014161801A1 Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
10/09/2014WO2014161095A1 Crp40 fragments for the treatment of neurological disorders
10/09/2014WO2014161037A1 Antibodies against human ryk and uses therefor
10/09/2014US20140303571 Titratable dosage transdermal delivery system
10/09/2014US20140303208 Pharmaceutically active piperidine derivatives
10/09/2014US20140302143 Controlled Release and Taste Masking Oral Pharmaceutical Compositions
10/09/2014US20140302139 Controlled Release and Taste Masking Oral Pharmaceutical Compositions
10/08/2014EP2786995A1 Azaindoles useful as inhibitors of JAK and other protein kinases
10/08/2014EP2786758A1 Pharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosyn
10/08/2014EP2786752A1 Ropinirole-containing adhesive patch
10/08/2014EP2785840A1 Induced exon inclusion in spinal muscle atrophy
10/08/2014EP2785729A1 Oligonucleotides for treating expanded repeat diseases
10/08/2014EP2785713A1 Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
10/08/2014EP2785711A1 2-(phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease
10/08/2014EP2785709A1 Aminopyrimidine derivatives as lrrk2 modulators
10/08/2014EP2785706A1 Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases
10/08/2014EP2785699A1 2-phenylaminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease
10/08/2014EP2785696A1 Novel compounds
10/08/2014EP2785691A1 Donepezil pamoate, preparation method and its use
10/08/2014EP2785379A1 Peptide-mediated delivery of active agents across the blood-brain barrier
10/08/2014EP2785378A1 Methods and compositions for increasing arylsulfatase a activity in the cns
10/08/2014EP2785364A1 Use of p3 of bacteriophage as amyloid binding agents
10/08/2014EP2785354A1 Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function
10/08/2014EP2785347A1 Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
10/08/2014EP2785344A1 Phacetoperane for the treatment of attention-deficit hyperactivity disorder
10/08/2014EP2785339A2 Metalloporphyrin neurological treatments
10/08/2014EP2785337A1 Acamprosate formulations, methods of using the same, and combinations comprising the same
10/07/2014US8853242 Nitrogenous-ring acylguanidine derivative
10/07/2014US8853216 Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
10/07/2014US8853203 Diazepinone derivatives
10/07/2014US8853199 Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
10/07/2014US8853193 Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
10/07/2014US8853166 Neurotrophic factor MANF and uses thereof
10/07/2014US8853160 GLP-1, exendin-4, peptide analogs and uses thereof
10/07/2014US8852656 Sleep improvement composition
10/07/2014US8852623 Implantable polymeric device for sustained release of dopamine agonist
10/02/2014WO2014160811A1 Compositions and methods for treating neuropathy
10/02/2014WO2014160502A1 Uridine nucleoside derivatives, compositions and methods of use
10/02/2014WO2014160480A1 Neuroactive steroids and methods of use thereof
10/02/2014WO2014160423A1 Methods and compositions for correction of organ dysfunction
1 ... 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 ... 1833